Susquehanna Portfolio Strategies, LLC
Position in ADCT — ADC Therapeutics SA
CIK 1996449
Bala Cynwyd, PA
Position in ADCT
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$30,884
-$211,077 QoQ
Shares Held
28,864
-55.3% QoQ
Ownership
0.023%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#62
of 113 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ADCT Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Susquehanna Portfolio Strategies, LLC holds $24,197,048 across 11 Drug Manufacturers - Specialty & Generic names. ADCT ranks #11 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SUPN |
Supernus Pharmaceuticals, Inc.
|
116,160 | $5,402,601 | |
| 2 | BCRX |
Biocryst Pharmaceuticals Inc
|
404,704 | $4,047,040 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
23,247 | $3,918,049 | |
| 4 | UTHR |
UNITED THERAPEUTICS Corp
|
6,701 | $3,630,802 | |
| 5 | ANIP |
Ani Pharmaceuticals Inc
|
28,047 | $2,321,730 | |
| 6 | AMRX |
Amneal Pharmaceuticals, Inc.
|
113,989 | $1,973,149 | |
| 7 | COLL |
Collegium Pharmaceutical, Inc
|
39,295 | $1,422,479 | |
| 8 | EBS |
Emergent BioSolutions Inc.
|
63,201 | $529,624 |
All Filings in ADCT
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $30,884 | 28,864 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $241,961 | 64,523 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $227,766 | 64,523 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $258,092 | 64,523 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $116,381 | 43,426 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||